We are live on
!
Find out more
AAP
Ardsley Advisory Partners Portfolio holdings
AUM
$960M
1-Year Est. Return
207.76%
This Fund
S&P 500
This Quarter
Est. Return
+62.68%
1 Year Est. Return
+207.76%
3 Year Est. Return
+554.53%
5 Year Est. Return
+728.66%
10 Year Est. Return
+4,084.52%
AUM
$470M
AUM Growth
+$215M
(+84%)
Cap. Flow
+$84.2M
Cap. Flow
% of AUM
17.91%
Top 10 Holdings %
Top 10 Hldgs %
50.14%
Holding
180
New
79
Increased
20
Reduced
20
Closed
47
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$19.9M |
| 2 |
T-Mobile US
TMUS
|
+$17.2M |
| 3 |
AbbVie
ABBV
|
+$12.5M |
| 4 |
Lumentum
LITE
|
+$11.5M |
| 5 |
Qualcomm
QCOM
|
+$10.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P Biotech ETF
XBI
|
+$8.88M |
| 2 |
FTAI Aviation
FTAI
|
+$8.81M |
| 3 |
STAAR Surgical
STAA
|
+$8.17M |
| 4 |
Sunrun
RUN
|
+$6.51M |
| 5 |
ZEN
ZENDESK INC
ZEN
|
+$6.08M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.99% |
| 2 | Healthcare | 17.02% |
| 3 | Consumer Staples | 13.31% |
| 4 | Industrials | 11.19% |
| 5 | Consumer Discretionary | 7.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
PUT
Wayfair
W
$12.5B
| $593K | 0.13% |
+3,000
| New | +$449K |
|
77
Humana
HUM
$46.7B
| $582K | 0.12% |
1,500
| – | – |
|
|
HOLX
78
DELISTED
Hologic
HOLX
| $570K | 0.12% |
+10,000
| New | +$491K |
|
|
79
CALL
Lumentum
LITE
$50.7B
| $570K | 0.12% |
+7,000
| New | +$533K |
|
80
Cigna
CI
$79.6B
| $563K | 0.12% |
3,000
| – | – |
|
81
Johnson & Johnson
JNJ
$643B
| $563K | 0.12% |
4,000
| – | – |
|
|
VIVO
82
DELISTED
Meridian Bioscience Inc
VIVO
| $547K | 0.12% |
+23,500
| New | +$341K |
|
|
83
State Street SPDR S&P Biotech ETF
XBI
$10.1B
| $543K | 0.12% |
4,850
-90,150
| -95% | -$8.88M |
|
|
IPHI
84
DELISTED
INPHI CORPORATION
IPHI
| $529K | 0.11% |
4,500
-10,500
| -70% | -$1.11M |
|
|
AWH
85
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
| $513K | 0.11% |
+8,905
| New | +$595K |
|
|
ZUO
86
DELISTED
Zuora, Inc.
ZUO
| $510K | 0.11% |
+40,000
| New | +$445K |
|
87
Expedia Group
EXPE
$35.5B
| $493K | 0.1% |
+6,000
| New | +$436K |
|
88
Cerus
CERS
$585M
| $462K | 0.1% |
70,000
| – | – |
|
|
MXIM
89
DELISTED
Maxim Integrated Products
MXIM
| $455K | 0.1% |
+7,500
| New | +$418K |
|
90
CALL
Teradata
TDC
$2.75B
| $416K | 0.09% |
+20,000
| New | +$435K |
|
|
MYOV
91
DELISTED
Myovant Sciences Ltd.
MYOV
| $412K | 0.09% |
+20,000
| New | +$272K |
|
92
Sanofi
SNY
$109B
| $403K | 0.09% |
+7,900
| New | +$384K |
|
93
Boston Scientific
BSX
$68.5B
| $386K | 0.08% |
+11,000
| New | +$396K |
|
94
BioMarin Pharmaceuticals
BMRN
$12B
| $370K | 0.08% |
+3,000
| New | +$298K |
|
95
Intuit
INTU
$85.6B
| $370K | 0.08% |
+1,250
| New | +$343K |
|
|
JNPR
96
DELISTED
Juniper Networks
JNPR
| $366K | 0.08% |
+16,000
| New | +$368K |
|
97
Tyler Technologies
TYL
$13.7B
| $347K | 0.07% |
+1,000
| New | +$336K |
|
|
98
CALL
Expedia Group
EXPE
$35.5B
| $329K | 0.07% |
+4,000
| New | +$291K |
|
|
FLXN
99
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $329K | 0.07% |
+25,000
| New | +$259K |
|
100
8x8 Inc
EGHT
$271M
| $328K | 0.07% |
+20,500
| New | +$326K |
|
Similar funds
NA
MK
QIM
JVBC
TFP
UWPG
LOAMU
PHS
Ardsley Advisory Partners's Q2 2020 Portfolio in Review
As of Q2 2020, Ardsley Advisory Partners held 180 positions worth $470M, up 84% from $255M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Ardsley Advisory Partners deployed $84.2M of net new capital in Q2 2020, opening 79 new positions and adding to 20 existing holdings. Its largest new stake was T-Mobile US: 179,510 shares worth $18.7M.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 21% a quarter earlier, followed by Healthcare and Consumer Staples.
On the sell side, the largest reduction was State Street SPDR S&P Biotech ETF, an estimated $8.88M trimmed.
- Ardsley Advisory Partners's largest Q2 2020 buy was T-Mobile US: 179,510 shares worth $18.7M.
- Ardsley Advisory Partners added most to Microsoft in Q2 2020, an estimated $19.9M increase.
- Ardsley Advisory Partners's biggest Q2 2020 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $8.88M.
- Ardsley Advisory Partners fully exited ZENDESK INC in Q2 2020, selling an estimated $6.08M.
- Ardsley Advisory Partners's ten largest holdings make up 50% of its $470M portfolio in Q2 2020.
- Ardsley Advisory Partners opened 79 new positions and closed 47 in Q2 2020.
- Ardsley Advisory Partners's portfolio value rose 84% quarter-over-quarter to $470M.
Based on Ardsley Advisory Partners's 13F filing for Q2 2020, filed 14 Aug 2020.